Medtronic (NYSE:MDT) has won FDA approval for a deep brain stimulation system for Parkinson’s disease. The approval is for ...
8don MSN
After decades of development and trials, Medtronic has secured U.S. Food and Drug Administration approval for adaptive ...
T here is still no cure for Parkinson’s disease, but the U.S. Food and Drug Administration (FDA) approved a new deep brain ...
Shortly after obtaining a greenlight in Europe and after more than 10 years in development, Medtronic has now received the ...
The FDA approved Medtronic's BrainSense Adaptive DBS and Electrode Identifier for Parkinson's, enhancing therapy ...
The biggest technical challenge for adaptive deep brain stimulation (aDBS) is how small brain signals are, Medtronic's Scott ...
The FDA approves BrainSense Adaptive deep brain stimulation and electrode identifier technology for the treatment of ...
The company's adaptive deep brain stimulation technology for Parkinson's disease therapy is expected to be available ...
Medtronic (MDT) announced FDA approval of BrainSense Adaptive deep brain stimulation – aDBS – and BrainSense Electrode Identifier. There is no ...
The brain-computer interface technology personalizes therapy based on an individual’s brain activity.
The FDA has approved BrainSense, an adaptive deep brain stimulation system that can adjust therapy for Parkinson’s disease in ...
9d
GlobalData on MSNFDA approves Medtronic’s brain stimulation system for Parkinson’sThe FDA’s authorisation of Medtronic’s BrainSense follows the system’s receipt of a CE mark in Europe last month.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results